Annals of Hematology

, Volume 87, Issue 4, pp 285–289

Rituximab therapy increased post-transplant cytomegalovirus complications in Non-Hodgkin’s lymphoma patients receiving autologous hematopoietic stem cell transplantation

  • Ming-Yang Lee
  • Tzeon-Jye Chiou
  • Liang-Tsai Hsiao
  • Muh-Hwa Yang
  • Pang-Chan Lin
  • Say-Bee Poh
  • Chueh-Chuan Yen
  • Jin-Hwang Liu
  • Hao-Wei Teng
  • Ta-Chung Chao
  • Wei-Shu Wang
  • Po-Min Chen
Original Article

DOI: 10.1007/s00277-007-0397-0

Cite this article as:
Lee, MY., Chiou, TJ., Hsiao, LT. et al. Ann Hematol (2008) 87: 285. doi:10.1007/s00277-007-0397-0

Abstract

The use of monoclonal antibody, rituximab, had been reported to be associated with some severe viral infections. The inference of rituximab therapy and post-transplant cytomegalovirus (CMV) infectious complications in non-Hodgkin’s lymphoma (NHL) patients is still unclear now. From 2002 to 2005, 46 patients with relapsed indolent or high-risk aggressive B cell NHL who received rituximab (17 patients) or not (29 patients) before autologous hematological stem cell transplantation (HSCT) in one institute were retrospectively analyzed for the risk factors of CMV complications after transplantation. Pre-transplant and post-transplant CMV infectious conditions, conditioning regimens, transplant types, and post-transplant complications were recorded. Post-transplant infectious complications were followed up until 6 months after transplantation.Seventeen of 46 patients received rituximab before HSCT. Three of them suffered from CMV infection and two of them developed CMV disease. All of the patients with CMV disease recovered after ganciclovir and CMV-specific immunoglobulin therapy. Twenty-nine of 46 patients without rituximab treatment before HSCT did not have CMV complications after HSCT. The risks to develop CMV infections after autologous HSCT were higher in rituximab-treated patients (17.6% vs 0%, p = 0.045, Fisher exact test, two-sided). The risks to develop CMV diseases had higher trend with rituximab therapy than without rituximab therapy (11.7% vs 0%, p = 0.131, Fisher exact test, two-sided). The NHL patients receiving rituximab therapy had higher risk to develop CMV infectious complications after autologous HSCT.

Keywords

Cytomegalovirus infection Rituximab therapy Hematopoietic stem cell transplantation Lymphoma 

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Ming-Yang Lee
    • 1
    • 2
  • Tzeon-Jye Chiou
    • 2
    • 3
    • 5
  • Liang-Tsai Hsiao
    • 2
    • 3
  • Muh-Hwa Yang
    • 2
    • 3
  • Pang-Chan Lin
    • 2
    • 3
  • Say-Bee Poh
    • 4
  • Chueh-Chuan Yen
    • 2
    • 3
  • Jin-Hwang Liu
    • 2
    • 3
  • Hao-Wei Teng
    • 2
    • 3
  • Ta-Chung Chao
    • 2
    • 3
  • Wei-Shu Wang
    • 2
    • 3
  • Po-Min Chen
    • 2
    • 3
  1. 1.Division of Hemato-Oncology, Department of MedicineChia-Yi Christian HospitalChia-YiRepublic of China
  2. 2.National Yang-Ming University School of MedicineTaipeiRepublic of China
  3. 3.Division of Hematology and Oncology, Department of MedicineTaipei Veterans General HospitalTaipeiRepublic of China
  4. 4.Division of Medical Oncology, Department of MedicinePing-Tung Christian HospitalPing TungRepublic of China
  5. 5.Division of Hematology and Oncology, Department of MedicineTaipei Veterans General HospitalTaipeiRepublic of China

Personalised recommendations